Zhengye Biotechnology Holding Limited Ordinary Shares Working Capital to Net Assets Ratio

Latest as of June 2025: 11.8%

Zhengye Biotechnology Holding Limited Ordinary Shares working capital to net assets ratio. Zhengye Biotechnology Holding Limited Ordinary Shares (ZYBT) has a Working Capital to Net Assets ratio of 11.8% as of June 2025. Working capital of $41.66 Million (current assets of $177.57 Million minus current liabilities of $135.91 Million) is measured against net assets of $352.54 Million. A higher ratio indicates strong short-term liquidity financed by the equity base. Check Zhengye Biotechnology Holding Limited Or tangible net worth ratio to evaluate the tangible quality of the company's equity base.

WC/NA Ratio

11.8%
Working Capital / Net Assets

Working Capital

$41.66 Million
USD

Current Assets

$177.57 Million
USD

Current Liabilities

$135.91 Million
USD

Working Capital to Net Assets Ratio of Zhengye Biotechnology Holding Limited Ordinary Shares (2021–2025)

Working capital to net assets ratio of Zhengye Biotechnology Holding Limited Ordinary Shares from 2021 to 2025. This chart shows how Zhengye Biotechnology Holding Limited Ordinary Shares's Working Capital to Net Assets ratio has evolved across 5 annual periods from 2021 to 2025. As of June 2025, the ratio stands at 11.8%, reflecting working capital of $41.66 Million against net assets of $352.54 Million USD. See Zhengye Biotechnology Holding Limited Or (ZYBT) liquidity interval to measure how many days the company can operate on defensive assets alone.

Zhengye Biotechnology Holding Limited Ordinary Shares Working Capital to Net Assets Ratio by Year (2021–2025)

Zhengye Biotechnology Holding Limited Ordinary Shares working capital to net assets ratio by year from 2021 to 2025. The table below presents the year-by-year Working Capital to Net Assets ratio for Zhengye Biotechnology Holding Limited Ordinary Shares from 2021 to 2025, covering 5 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For the complete balance sheet picture, see Zhengye Biotechnology Holding Limited Or balance sheet assets.

Year WC/NA Ratio Working Capital (USD) Net Assets Current Assets Current Liabilities Change (pp)
2025 11.8% $41.66 Million $352.54 Million $177.57 Million $135.91 Million ▲ +0.0 pp
2024 11.8% $41.66 Million $352.54 Million $177.57 Million $135.91 Million ▼ -4.5 pp
2023 16.3% $55.36 Million $339.27 Million $205.59 Million $150.23 Million ▼ -1.1 pp
2022 17.4% $62.08 Million $356.87 Million $214.31 Million $152.23 Million ▲ +5.1 pp
2021 12.3% $39.32 Million $318.84 Million $164.94 Million $125.63 Million —
pp = percentage points